FIIs bought 24,84,000 shares & Government of India bought 1,28,000 shares: Pharma penny stock under Rs 30 jumps over 7% from day’s low

On Wednesday, shares of Sudarshan Pharma Industries Ltd jumped 7.61 per cent to Rs 27.02 per share from its day’s low of Rs 25.11 per share. The shares of the company saw a spurt in volume by more than 1.3 times on the BSE. The stock’s 52-week high is Rs 53.50 per share while its 52-week low is Rs 11.80 per share.

Sudarshan Pharma Industries Limited (SPIL), established in 2008 and headquartered in Mumbai, is a prominent contract manufacturer of generic formulations. SPIL caters to a wide range of institutions and healthcare organisations operating across diverse segments, including speciality chemicals, intermediates, APIs, pharmaceutical and formulation generics, and bulk supply. Beyond its contract manufacturing services, SPIL has ventured into branded products through its Vimac Healthcare division. A significant portion of its product portfolio, consisting of 56 out of 96 items, is registered under the "R" trademark. Furthermore, SPIL collaborates with renowned Indian companies and institutional clients, offering contract manufacturing services for pharmaceutical formulations and medicines.

SPIL is expanding its global footprint by establishing two wholly-owned subsidiaries. The Board has approved the incorporation of a subsidiary in Canada and another in the United States, proposed to be named "Sudarshan Industries LLC." Both subsidiaries will focus on the manufacturing and trading of chemical, pharmaceutical, general, and FMCG products. These international ventures are subject to necessary approvals from the Reserve Bank of India under the Foreign Exchange Management Act and its related regulations, enabling SPIL to establish a direct business presence in these key foreign markets.

According to the half-yearly results, the net sales increased by 19 per cent to Rs 277 crore and net profit increased by 43 per cent to Rs 7 crore in H2FY25 compared to H2FY24. In its annual results, the net sales increased by 9 per cent to Rs 505 crore and net profit increased by 45 per cent to Rs 16 crore in FY25 compared to FY24. The company has a market cap of Rs 645 crore and has delivered good profit growth of 37 per cent CAGR over the last 5 years.

In June 2025, FIIs bought 24,84,000 shares and increased their stake by 19.49 per cent compared to March 2025. Additionally, the  Government of India took a fresh entry and bought 1,28,000 shares or 0.05 per cent stake in the company. The stock gave multibagger returns of 129 per cent from its 52-week low of Rs 27.02 per share and a whopping 315 per cent in 2 years.

Disclaimer: The article is for informational purposes only and not investment advice.